Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Moderna

Here's How Much $1000 Invested In Moderna 5 Years Ago Would Be Worth Today

Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 105.44% on an annualized basis producing an average annual return of 116.6%. Currently, Moderna has a market capitalization of $56.68 billion.

Benzinga

Moderna And 3 Other Stocks Insiders Are Selling

US crude oil futures traded lower, dropping around 0.5% on Monday. Investors, meanwhile, focused on some notable insider trades.

Benzinga

Morning Brief: Top Financial Stories Dominating on Monday, May 16

CNBC Volkswagen CEO Shares Ambitious EV Ambitions For US Market

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Australia risks relying on Pfizer and Moderna for its COVID vaccines. 3 ways to break free

The rapid development and deployment of COVID vaccines has been one of the greatest achievements of the pandemic.

The Conversation

Biden administration and GOP clash over vaccine strategy

The administration wants to keep access as open as possible, but the GOP wants to reduce wastage.

Axios

Why Did Moderna CFO Exit Just A Day After Taking Charge

Moderna Inc (NASDAQ:MRNA) announced that its recently appointed Chief Financial Officer, Jorge Gomez, has departed the company, effective immediately. The announcement follows the public disclosure by Gomez's former employer, Dentsply Sirona Inc (NASDAQ:XRAY), of an ongoing internal investigation into some issues, including financial reporting. The audit investigates Dentsply Sirona's "use of incentives to sell products to…

Benzinga

Why Moderna Shares Are Trading Lower Following Novavax's Earnings Report

Moderna Inc (NASDAQ: MRNA) shares are trading lower by 3.15% at $131.52.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Fourth Covid booster vaccine 'significantly' improves protection over just three jabs

It is "over and above" the level of protection that people who have had their third jab receive, according to the latest research.

Daily Record

Covid vaccines safe for pregnant women and cut stillbirth risk, says review

Chance of stillbirth reduced by 15%, researchers find, after examining studies and trials that enrolled 117,552 women

The Guardian - UK

Fourth booster ‘significantly’ increases Covid protection

Levels of antibodies waned in period between third jabs and fourth boosters

Wales Online

Covid: ‘Vaccine ceiling’ approaching for some as study suggests fourth jab may not be necessary

A ‘hint’ that some people might have already reached ‘ceiling’ in terms of protection they could acquire from fourth jab

The Independent UK

Morning Brief: Top Financial Stories Dominating on Monday, May 9

CNBC Ford Motor Selling 8M Shares Of Rivian Automotive

Benzinga

Moderna Files Motion To Dismiss COVID-19 Vaccine Related Patent Claims: WSJ

Moderna Inc (NASDAQ: MRNA) is trying to fight off rival companies’ patent infringement claims related to its COVID-19 vaccine, arguing that the companies may only pursue their claims by seeking royalties from the federal government.

Benzinga

Looking At Moderna's Recent Whale Trades

Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Asharq Al-Awsat

US Drug Regulator Limits Use of J&J Covid Vaccine

The US said Thursday only adults who "have personal concerns" about mRNA vaccines, access issues or medical reasons for refusing them may now receive the Johnson & Johnson Covid shot, which has been linked to a rare but serious clotting condition. The vaccine, which was authorized as a single shot,…

Benzinga

Check Out What Whales Are Doing With MRNA

Benzinga

Where Moderna Stands With Analysts

Analysts have provided the following ratings for Moderna (NASDAQ:MRNA) within the last quarter:

Los Angeles Times

Commentary: COVID won’t become endemic until we have a vaccine for kids under 5

Last week, Moderna became the first manufacturer to officially ask the Food and Drug Administration to approve its COVID-19 vaccine for children under 6 years old. One of three companies with authorized COVID-19 vaccines in the United States, Moderna made the request a month after saying its data showed efficacy…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Mid-Day Market Update: Dow Rises 100 Points; Lyft Shares Plummet

U.S. stocks traded mixed midway through trading, with the Dow Jones gaining more than 100 points on Wednesday.

Benzinga

Mid-Morning Market Update: Markets Mixed; Nasdaq Tumbles 100 Points

U.S. stocks traded mixed this morning, with the Nasdaq dropping more than 100 points on Wednesday.

The Conversation

Will new vaccines be better at fighting coronavirus variants? 5 questions answered

The first three coronavirus vaccines earned Emergency Use Authorization more than a year ago. To date, no other vaccines have been put into use in the U.S – but that will soon change. More than 40 vaccines are undergoing clinical trials in the U.S., employing a number of different approaches…

Benzinga

Here's Why Moderna Shares Are Trading Higher After Q1 Earnings Today

Moderna Inc (NASDAQ:MRNA) reports a Q1 EPS of $8.58, compared to the $2.84 posted a year ago, handsomely beating the consensus estimate of $5.21. Total revenue was $6.1 billion compared to $1.9 billion in Q1 FY21, primarily due to increased product sales. The revenue consensus was $4.43 billion. Product sales were $5.9…

Benzinga

Moderna: Q1 Earnings Insights

Moderna (NASDAQ:MRNA) reported its Q1 earnings results on Wednesday, May 4, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

The Independent UK

Pfizer hopes to submit little-kid vaccine data by early June

Pfizer now hopes to tell U.S. regulators how well its COVID-19 vaccine works in the littlest kids by early June

The Guardian - UK

Pfizer accused of Covid profiteering as first-quarter sales hit $26bn

Pharma firm criticised over pricing and for keeping monopoly control over vaccine and new Paxlovid pill

1 … 25 26 27 28

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations